510(k) Summary per 21 CFR 807.92

DEC 2 0 2013

Submitter

Nipro Medical Corporation 3150 NW 107th Avenue

Miami, FL 33172

FDA Establishment #: 1056186

Contact Person

Jessica Oswald-McLeod Phone: 305-599-7174

Fax: 305-592-4621

Date of Preparation

June 21, 2013

Device Trade Names

Nipro ELISIOTM-H Hemodialyzer Nipro ELISIOTM-M Hemodialyzer

Device Classification

Name

High permeability hemodialysis system

per 21CFR 876.5860

Common Name

Hemodialyzer

Substantial Equivalence

K122347

ELISIOTM-H and ELISIOTM-M Hemodialyzers

Device Description

The ELISIO-H and ELISIO-M hemodialyzers are medical devices used as an artificial kidney system for the treatment of patients with renal failure. During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the

blood to the dialysate compartment.

The ELISIO-H and ELISIO-M dialyzers are composed of polyethersulfone fiber and are available in various sizes, which are differentiated by membrane surface

area.

Intended Use

Hemodialysis with an ELISIOTM_H or an ELISIOTM_M hemodialyzer is indicated for patients with acute or chronic renal failure when conservative therapy is judged to be inadequate. It also may be indicated in the treatment of patients intoxicated with poisons or drugs.

The device is for prescription use only. This product is intended for single use only. The performance properties of reused dialyzers have not been established.

Technological Aspects

Both the ELISIO-H and ELISIO-M dialyzers and the predicate dialyzers are composed of polyethersulfone fiber. The membrane composition is identical between the ELISIO dialyzers and the predicate devices. The modification is a replacement of the polycarbonate casing (housing case and blood traps) of the ELISIO hemodialyzers with a polypropylene casing.

Non-clinical studies included those to assess biocompatibility. Results of these studies establish substantial equivalence to predicate device.

Conclusion

Testing performed on the ELISIO-H and ELISIO-M dialyzers indicates that they are safe, effective and perform as well as the predicate devices, when used in accordance with the instructions for use.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

December 20, 2013

Nipro Medical Corporation Regulatory Affairs % Carolyn K. George Consultant 3150 NW 107th Avenue Miami, FL 33172

Re: K131935

Trade/Device Name: ELISIOTM-H and ELISIOTM-M Hemodialyzers

Regulation Number: 21 CFR 876.5860

Regulation Name: High permeability hemodialysis system

Regulatory Class: Class II Product Code: KDI

Dated: November 21, 2013 Received: November 25, 2013

Dear Carolyn George,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Elaine Blyskun Acting for

Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number: K131935

Device Name: ELISIO™-H and ELIS	IO™-M hemodi	alyzers
Indications for Use:		
patients with acute or chronic re	enal failure wher	OTM-M hemodialyzer is indicated for a conservative therapy is judged to be ment of patients intoxicated with poisons
The device is for prescription u	se only.	
This product is intended for sin dialyzers have not been establis	· ·	e performance properties of reused
	•	
Prescription Use X (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELO	W THIS LINE-C NEEDED)	CONTINUE ON ANOTHER PAGE OF

Concurrence of CDRH, Office of Device Evaluation (ODE)

Elaine Blyskun

for Benjamin Fisher

Page 1 of 1